TNYA News & Events

Tenaya Therapeutics presented preclinical data evaluating TN-301, the company's highly selective HDAC6 inhibitor, at the Muscular Dystrophy Association's Clinical & Scientific Conference 2026. In in vitro and in vivo models of Duchenne muscular dystrophy, TN-301 improved muscle performance and corrected key drivers of DMD cardiomyopathy. Key findings presented at MDA 2026 include: TN-301 treatment at doses as low as 3 mg/kg improved grip strength to wild-type levels within five weeks, whereas mdx mice treated with givinostat failed to reach wild-type performance. TN-301-mediated functional improvements were accompanied by reductions in circulating creatine kinase activity and favorable changes in gene expression, indicating reduced muscle cell injury. In cardiomyocytes derived from human DMD induced pluripotent stem cells, TN-301 corrected calcium handling abnormalities and mitochondrial dysfunction, while givinostat exacerbated these established drivers of DMD cardiomyopathy.

Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY) to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases. "This multi-target collaboration underscores Tenaya's commitment to rigorous science and capitalizes on the proprietary capabilities that have contributed to the discovery and development of Tenaya's pipeline of candidates for cardiovascular conditions," said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. "By combining our modality agnostic target identification and validation capabilities with Alnylam's leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease."

Tenaya Therapeutics provided an update on its clinical development programs and outlined its strategic priorities for 2026. "2025 was a momentous year for Tenaya as we demonstrated early evidence of safety and potentially disease-modifying activity for our gene therapy programs for MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy-devastating inherited heart conditions with limited treatment options," said Faraz Ali, Chief Executive Officer of Tenaya. "These encouraging results offer real hope to patients and families in need of transformative therapies. On the strength of these data, we successfully raised additional capital to advance both programs through key clinical milestones in 2026, including more mature data readouts from both programs. We remain steadfast in our mission to deliver potentially curative therapies for those living with serious genetic heart diseases."